GlassScriptPhysician profile
Randi M Toth
NPI 1710356902
$4,021.10
in general payments reported to CMS, 2019-2025
24 companies · $1,208 in 2025
The $1,208 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $709 · 2022: $469 · 2023: $1,040 · 2024: $596 · 2025: $1,208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,568 · Education: $276.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,568.09 |
| Education | $275.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $948.06 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Abbvie INC. | $766.70 | 2021-2025 | |
| Lilly USA, LLC | $335.56 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Genzyme Corporation | $253.52 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $221.52 | 2021-2025 | Dupixent |
| Incyte Corporation | $209.38 | 2021-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $182.59 | 2021-2025 | |
| Ucb, INC. | $176.03 | 2023-2025 | Bimzelx, Cimzia |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $161.26 | 2021-2025 | Jublia, Arazlo, Cabtreo |
| Amgen INC. | $149.79 | 2021-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $137.22 | 2021-2025 | |
| Galderma Laboratories, L.P. | $109.62 | 2023-2025 | Nemluvio, Aklief, Oracea |
| Pfizer INC. | $91.79 | 2022-2025 | |
| Leo Pharma INC. | $59.27 | 2022-2025 | Anzupgo |
| Almirall LLC | $48.87 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $26.51 | 2023 | |
| Journey Medical Corporation | $21.26 | 2022 | |
| Pierre Fabre Pharmaceuticals, INC. | $19.87 | 2025 | Hemangeol |
| Allergan, INC. | $19.79 | 2022 | |
| Vyne Pharmaceuticals INC. | $19.27 | 2021 | |
| Biofrontera INC. | $18.67 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Dermavant Sciences, INC. | $15.60 | 2023 | Vtama |
| Strata Skin Sciences, INC. | $15.35 | 2025 | Xtrac |
| Epi Health, LLC | $13.60 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randi Toth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.